Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL6266322 | 0.89 | CA2 (0.44) | CA2MAPTKDM4ETP53 | |
| SCHEMBL6266333 | 0.89 | CA2 (0.46) | CA2MAPTKDM4ETP53 | |
| SCHEMBL18174873 | 0.87 | CA2 (0.44) | CA2MAPTKDM4ETP53 | |
| SCHEMBL18461167 | 0.84 | CA2 (0.42) | CA2MAPTKDM4ETP53 | |
| SCHEMBL3392720 | 0.84 | CA2 (0.44) | CA2MAPTKDM4ETP53 | |
| SCHEMBL24451382 | 0.83 | KDM4E (0.47) | CA2MAPTKDM4ETP53 | |
| SCHEMBL3389623 | 0.83 | CA2 (0.47) | CA2MAPTKDM4ETP53 | |
| SCHEMBL11452068 | 0.83 | CA2 (0.43) | CA2MAPTKDM4ETP53 | |
| SCHEMBL21090601 | 0.82 | CA2 (0.42) | CA2MAPTKDM4ETP53 | |
| SCHEMBL11459577 | 0.81 | CA2 (0.41) | CA2MAPTKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160332950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF UREA CYCLE DISORDERS AND GOUT | ALAPATI MOHAN MURALI (IN) | 2016-11-17 | — | — | US | disclosed |
| US-9475747-B1 | Compositions and methods for the treatment of urea cycle disorders and gout | ALAPATI MOHAN MURALI (IN) | 2016-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF UREA CYCLE DISORDERS AND GOUT | SLC14A1, UMPS, UGT1A3 | CA2 2420/4885MAPT 599/4885KDM4E 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.